Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Jim Cramer recommends five small-cap health-care stocks
06:51pm, Friday, 05'th Apr 2024
CNBC's Jim Cramer said he thinks it could be a good year for small cap stocks and shared his top picks.
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
12:37pm, Friday, 29'th Mar 2024
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
08:03am, Thursday, 28'th Mar 2024
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
08:03am, Wednesday, 27'th Mar 2024
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
07:44am, Wednesday, 27'th Mar 2024
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as di
7 Biotech Stocks Ready to Ride the Sector's Resurgence
08:01pm, Monday, 18'th Mar 2024
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
02:00am, Thursday, 14'th Mar 2024
Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in the Un
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
07:55am, Wednesday, 13'th Mar 2024
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
03:24pm, Sunday, 10'th Mar 2024
If you want big returns, you gotta think small – as in small-cap stocks. That's not to say the large-capitalization enterprises can't get you to investment Valhalla.
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
09:30am, Tuesday, 05'th Mar 2024
Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
08:03am, Tuesday, 05'th Mar 2024
CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, d
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
01:11pm, Thursday, 29'th Feb 2024
Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
08:21pm, Wednesday, 28'th Feb 2024
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.22 per share a year ago.
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
08:03am, Wednesday, 14'th Feb 2024
The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET
